Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months ...
